FDA
-
-
-
-
-
-
-
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
-
-
-
-
-
-
-
Helus Pharma completes enrollment in Phase 3 depression study
-
-
-
-
-
-
-
Helus Pharma prices $50M share offering at $4.85 per share
-
-
-
-
-
-
-
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthÂ
-
-
-
-
-
-
-
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
-
-
-
-
-
-
-
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
-
-
-
-
-
-
-
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
-
330,681 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

